948 Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC

• Christian Mueller,
• Frederik Marmé,
• Luc Dirix,
• Frederic Triebel,
• Hans Wildiers,
• Peter Vuylsteke,
• Chrystelle Brignone,
• Jens Huober,
• Sherko Kümmel,
• Anne Armstrong,
• Eveline De Cuypere,
• Florence Dalenc,
• Steven Chan,
• Carolina Pia Schröder,
• Jean-Philippe Jacquin,
• Etienne Brain,
• Zsuzsanna Pápai

Affiliations

Christian Mueller

13Immutep, Berlin, Germany

Frederik Marmé

Gynecological Oncology, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany

Luc Dirix

Aff5 Saint-Augustinus Hospital Antwerp Belgium

Frederic Triebel

13Immutep, Berlin, Germany

Hans Wildiers

Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium

Peter Vuylsteke

14 Department of Medical Oncology, CHU UCL Namur, Namur, Belgium

Chrystelle Brignone

12Immutep S.A.S, Paris, France

Jens Huober

Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany

Sherko Kümmel

9Kliniken Essen-Mitte, Essen, Germany

Anne Armstrong

3The Christie NHS Foundation Trust, Manchester, UK

Eveline De Cuypere

4AZ Sint-Jan Brugge-Oostende AV, Ruddershove, Belgium

Florence Dalenc

5Institut Claudius Regaud (Institut Claudius regaud- Institut Universitaire du Cancer – Oncopole), Toulouse, France

Steven Chan

6Nottingham Cancer Clinical Trials Team, Nottingham, UK

Carolina Pia Schröder

8University Medical Center Groningen, Groningen, Netherlands

Jean-Philippe Jacquin

11Institut de Cancérologie de la Loire, Saint Priest en Jarez, France

Etienne Brain

12Institut Curie -Hôpital René Huguenin, Saint-Cloud, France

Zsuzsanna Pápai

14MH Egészségügyi Központ Onkológiai, Budapest, Hungary